Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:MTVA NASDAQ:MURA NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.70+4.9%$1.72$0.51▼$2.86$94.73M-0.1597,577 shs31,878 shsMTVAMetaVia$0.98+2.0%$0.89$0.56▼$3.12$23.71M0.37101,274 shs21,091 shsMURAMural Oncology$2.09$2.07$0.95▼$4.74$36.21M2.93121,577 shs212,022 shsSTTKShattuck Labs$1.92+3.8%$1.80$0.69▼$2.71$91.97M1.89402,344 shs100,762 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma0.00%-1.73%+0.59%-23.42%+39.34%MTVAMetaVia0.00%+0.75%-2.00%+38.99%+97,999,900.00%MURAMural Oncology0.00%+0.97%0.00%-13.64%-39.42%STTKShattuck Labs0.00%+6.08%-16.16%+126.90%+47.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.70+4.9%$1.72$0.51▼$2.86$94.73M-0.1597,577 shs31,878 shsMTVAMetaVia$0.98+2.0%$0.89$0.56▼$3.12$23.71M0.37101,274 shs21,091 shsMURAMural Oncology$2.09$2.07$0.95▼$4.74$36.21M2.93121,577 shs212,022 shsSTTKShattuck Labs$1.92+3.8%$1.80$0.69▼$2.71$91.97M1.89402,344 shs100,762 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma0.00%-1.73%+0.59%-23.42%+39.34%MTVAMetaVia0.00%+0.75%-2.00%+38.99%+97,999,900.00%MURAMural Oncology0.00%+0.97%0.00%-13.64%-39.42%STTKShattuck Labs0.00%+6.08%-16.16%+126.90%+47.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 2.67Moderate Buy$7.00311.76% UpsideMTVAMetaVia 2.33Hold$7.50665.31% UpsideMURAMural Oncology 2.20Hold$12.00474.16% UpsideSTTKShattuck Labs 2.50Moderate Buy$3.0056.25% UpsideCurrent Analyst Ratings BreakdownLatest MTVA, MURA, CNTB, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025MTVAMetaViaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/25/2025STTKShattuck LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025CNTBConnect BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CNTBConnect BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MTVAMetaViaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MURAMural OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025STTKShattuck LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CNTBConnect BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MTVAMetaViaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MURAMural OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025STTKShattuck LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M3.64N/AN/A$1.67 per share1.02MTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/AMURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ASTTKShattuck Labs$5.72M16.08N/AN/A$1.67 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$15.63M-$0.42N/AN/AN/AN/AN/AN/AN/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-212.00%-107.21%11/6/2025 (Estimated)MURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%11/12/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest MTVA, MURA, CNTB, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025STTKShattuck Labs-$0.15N/AN/AN/AN/AN/A11/12/2025N/AMURAMural Oncology-$0.59N/AN/AN/AN/AN/A11/6/2025Q3 2025MTVAMetaVia-$0.26N/AN/AN/AN/AN/A8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/A8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.017.247.24MTVAMetaViaN/A2.082.08MURAMural OncologyN/A2.872.87STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%MTVAMetaVia1.37%MURAMural Oncology80.21%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%MTVAMetaVia0.80%MURAMural Oncology2.20%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableMTVAMetaVia824.20 million24.00 millionN/AMURAMural Oncology11917.33 million16.94 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableMTVA, MURA, CNTB, and STTK HeadlinesRecent News About These CompaniesShattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 TranscriptOctober 10, 2025 | seekingalpha.comShattuck Labs (NASDAQ:STTK) Given Sell (D-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comWhat Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?October 8, 2025 | zacks.comShattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by AnalystsOctober 3, 2025 | marketbeat.comShort Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Drops By 61.0%October 2, 2025 | marketbeat.comShattuck Labs, Inc. to Participate in Panel Discussion at UEGW Conference 2025October 2, 2025 | quiverquant.comQShattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company PanelOctober 2, 2025 | globenewswire.comGoldman Sachs Group Inc. Decreases Stake in Shattuck Labs, Inc. $STTKOctober 1, 2025 | marketbeat.comShattuck Labs files to sell 105.27M shares of common stock for holdersSeptember 19, 2025 | msn.comShould You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?September 19, 2025 | zacks.comShattuck Labs Inc : STTKSeptember 17, 2025 | 247wallst.comWedbush Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationSeptember 9, 2025 | msn.comShattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?September 8, 2025 | zacks.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3, 2025 | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comShattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 22, 2025 | finanznachrichten.deShattuck Labs says IND for SL-325 for treatment of IBD in effectAugust 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, MURA, CNTB, and STTK Company DescriptionsConnect Biopharma NASDAQ:CNTB$1.70 +0.08 (+4.94%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$1.63 -0.07 (-4.12%) As of 10/24/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.MetaVia NASDAQ:MTVA$0.98 +0.02 (+1.97%) As of 10/24/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Mural Oncology NASDAQ:MURA$2.09 0.00 (0.00%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.11 +0.02 (+0.96%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Shattuck Labs NASDAQ:STTK$1.92 +0.07 (+3.78%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 10/24/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
